Skip to content
HowShorted

Beam Therapeutics Inc. short interest in 2023

In 2023, Beam Therapeutics Inc.'s disclosed short interest ran from 18.46% of shares outstanding on 13 Jan 2023 to 16.55% on 29 Dec 2023, a change of -1.91 percentage points. The year's high was 19.74% on 15 Mar 2023 and its low 15.74% on 31 Jul 2023, averaging 17.35% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 19.63 days on 31 Aug 2023. Full history: Beam Therapeutics Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Beam Therapeutics Inc. in 2023

2023 in figures

Start of year
18.46% (13 Jan 2023)
End of year
16.55% (29 Dec 2023)
Change
-1.91 pp
High
19.74% (15 Mar 2023)
Low
15.74% (31 Jul 2023)
Average
17.35%
Highest days to cover
19.63 (31 Aug 2023)
SEC filings marked
9

Every report in 2023

Beam Therapeutics Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 202318.46%15.23results (8-K)
31 Jan 202317.62%18.92
15 Feb 202316.95%14.09
28 Feb 202317.71%13.5610-K filed, results (8-K)
15 Mar 202319.74%11.49
31 Mar 202319.31%13.72
14 Apr 202318.27%13.40
28 Apr 202318.07%16.38
15 May 202317.26%14.2210-Q filed, results (8-K)
31 May 202316.42%15.24
15 Jun 202316.34%18.69
30 Jun 202316.57%14.00
14 Jul 202316.35%14.75
31 Jul 202315.74%14.40
15 Aug 202316.49%13.3110-Q filed, results (8-K)
31 Aug 202316.58%19.63
15 Sep 202317.06%14.02
29 Sep 202318.12%16.85
13 Oct 202319.06%17.08
31 Oct 202318.25%9.17
15 Nov 202316.96%7.6710-Q filed, results (8-K)
30 Nov 202315.95%8.18
15 Dec 202316.53%11.01
29 Dec 202316.55%8.95

See also: Beam Therapeutics Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.